Alexandre T. D. N.
- Country
- France
- Department
- Oncology
Research Overview
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
Data & Insights
Has run more than one trial at 265 of 518 partner sites.
Specializations
Triple Negative Breast Cancer Research
The investigator specializes in treating triple negative breast cancer, with particular focus on post-operative and neoadjuvant therapeutic approaches. Their research encompasses innovative combinations of capecitabine and immunotherapy treatments for patients with residual disease.
- Post-operative treatment strategies
- Neoadjuvant chemo-immunotherapy
- Residual disease management
HER2-Positive Breast Cancer Studies
The investigator conducts extensive research in HER2-positive breast cancer treatment modalities, including studies of novel targeted therapies and maintenance treatments. Their work involves evaluating trastuzumab-based combinations and investigating therapeutic de-escalation strategies.
- Advanced and metastatic disease
- Targeted therapy optimization
- Maintenance treatment protocols
Hormone Receptor-Positive Disease
The investigator focuses on developing treatments for hormone receptor-positive breast cancer, particularly in advanced and metastatic settings. Their research includes evaluation of endocrine therapy combinations and novel therapeutic approaches for patients with specific genetic mutations.
- Early-stage breast cancer management
- Advanced disease treatment strategies
- Endocrine therapy resistance
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.